The Region of the Americas comprises 46 countries and territories and Brazil and Peru are among the WHO high- TB burden
countries. T o illustrate the recent increase in TB incidence in the region, we selected 12 countries from Latin America (Argentina,
Brazil, Chile, Colombia, Ecuador, El Salvador..., Mexico, Panama, Paraguay, Peru, Uruguay and Venezuela), which account for approximately 80% of the total estimated TB cases in the region.
more
Die durch den Forschungsbereich Migration, Flucht und Integration der FAU durchgeführte Studie untersucht Themengebiete rund um Migration und Integration in Deutschland. Auf Grundlage einer umfassenden Desktop-Recherche sowie anhand eines Scenario-Buildings entwarf die Studie mit einem interdiszipl...inären Expert*innenteam aus ganz Deutschland ein Zukunftsbild anhand der Frage: Wie sieht Integration in Deutschland im Jahr 2030 aus?
more
Das Forschungszentrum des BAMF untersuchte im Auftrag des Bundesministeriums des Innern, für Bau und Heimat, inwieweit die konzeptionelle Idee der AnkER-Einrichtungen und funktionsgleichen Einrichtungen, alle beteiligten Akteure unter einem Dach zu vereinen, in den unterschiedlichen Phasen der Asyl...verfahrensbearbeitung zu Effizienz- und Effektivitätssteigerungen führt.
more
Der Policy Brief des Kompetenznetz Public Health COVID-19 befasst sich mit der empirischen Evidenz zu SARS-Cov-2 bei Migrant*innen und geflüchteten Menschen und leitet hieraus Handlungsempfehlungen ab. Eine Kernbotschaft des Papiers ist, dass das Risiko von SARS-CoV-2 Neuinfektionen unter Migrant*i...nnen im Vergleich zu Nicht-Migrant*innen höher ist, Krankenhauseinweisungen hingegen seltener sind.
more
Global Qualitative Nursing Research March 31, 2021 Research Article Find in PubMed
https://doi.org/10.1177/23333936211005475
Introduction: Considering the global prevalence of coronavirus disease 2019 (COVID-19), a vaccine is being developed to control the disease as a complementary solution to hygiene measures—and better, in social terms, than social distancing. Given that a vaccine will eventually be produced, informa...tion will be needed to support a potential campaign to promote vaccination.
Objective: The aim of this study was to determine the variables affecting the likelihood of refusal and indecision toward a vaccine against COVID-19 and to determine the acceptance of the vaccine for different scenarios of effectiveness and side effects.
Materials and Methods: A multinomial logistic regression method based on the Health Belief Model was used to estimate the current methodology, using data obtained by an online anonymous survey of 370 respondents in Chile.
Results: The results indicate that 49% of respondents were willing to be vaccinated, with 28% undecided or 77% of individuals who would potentially be willing to be inoculated. The main variables that explained the probability of rejection or indecision were associated with the severity of COVID-19, such as, the side effects and effectiveness of the vaccine; perceived benefits, including immunity, decreased fear of contagion, and the protection of oneself and the environment; action signals, such as, responses from ones' family and the government, available information, and specialists' recommendations; and susceptibility, including the contagion rate per 1,000 inhabitants and relatives with COVID-19, among others. Our analysis of hypothetical vaccine scenarios revealed that individuals preferred less risky vaccines in terms of fewer side effects, rather than effectiveness. Additionally, the variables that explained the indecision toward or rejection of a potential COVID-19 vaccine could be used in designing public health policies.
Conclusions: We discovered that it is necessary to formulate specific, differentiated vaccination-promotion strategies for the anti-vaccine and undecided groups based on the factors that explain the probability of individuals refusing or expressing hesitation toward vaccination.
more
Mass vaccination campaigns to prevent coronavirus disease 2019 (Covid-19) are occurring in many countries; estimates of vaccine effectiveness are urgently needed
to support decision making. A countrywide mass vaccination campaign with the
use of an inactivated severe acute respiratory syndrome c...oronavirus 2 (SARS-CoV-2)
vaccine (CoronaVac) was conducted in Chile starting on February 2, 2021.
more
Challenged by the health emergency, Primary Health Care (PHC) professionals remodeled their work processes and realized that many of the innovations implemented in an emergency manner to respond to the pandemic of COVID are here to stay. The initiative APS Forte no SUS - no combate à pandemia de CO...VID-19 gathered experiences from all over the country, executed by engaged health workers who, despite the difficulties imposed by the new disease, fight daily to improve the offer and care in health in the Unified Health System (SUS). With the help of digital technologies, teams and professionals of the Family Health Strategy overcome daily one of the main challenges of APS in this pandemic: ensuring access to health services. Digital tools gain strength in the agenda for strengthening the SUS, so well represented in this initiative.
more
Ein Leitfaden für die Zusammenarbeit mit Dolmetscher_innen in Frauenhäusern und mit Fachberatungsstellen
Annals of Global Health, 87(1), p.30. DOI: http://doi.org/10.5334/aogh.2647
The Lancet Planetary Health, Vol.5 Issue 2, Feb. 1,2021.
Nationally determined contributions (NDCs) serve to meet the goals of the Paris Agreement of staying “well below 2°C”, which could also yield substantial health co-benefits in the process. However, existing NDC commitments are inadequa...te to achieve this goal. Placing health as a key focus of the NDCs could present an opportunity to increase ambition and realise health co-benefits. We modelled scenarios to analyse the health co-benefits of NDCs for the year 2040 for nine representative countries (ie, Brazil, China, Germany, India, Indonesia, Nigeria, South Africa, the UK, and the USA) that were selected for their contribution to global greenhouse gas emissions and their global or regional influence.
more
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...r vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
“Guide to facilitate the implementation of the WHO/UNICEF “Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines” for Africa
t contains action-oriented lists of critical topics to address and checklists tailored to the context of African Union Member States.
...
The contents of this guide aim to guide the development of one comprehensive national deployment and vaccination plan, as proposed and outlined by the guidance – and underlines the need for countries to develop their vaccination plans.
This guide is not meant as a tool to assess deployment readiness. The recommendation to Member States is to use the VIRAT/VRAF 2.0 tool for that, which builds on the COVAX Vaccine Introduction Readiness Assessment Tool (VIRAT) and the World Bank’s Vaccine Readiness Assessment Framework (VRAF).
more
Waste Management & Research 39(1) DOI: 10.1177/0734242X211029175
13 April 2021 Policy Brief